Lung cancer is a devastating disease that remains a top cause of cancer mortality. Despite improvements with targeted and immunotherapies, the majority of patients with lung cancer lack effective therapies, underscoring the need for additional treatment approaches. Genomic studies have identified frequent alterations in components of the SWI/SNF chromatin remodeling complex including SMARCA4 and ARID1A. To understand the mechanisms of tumorigenesis driven by mutations in this complex, we developed a genetically engineered mouse model of lung adenocarcinoma by ablating Smarca4 in the lung epithelium. We demonstrate that Smarca4 acts as a bona fide tumor suppressor and cooperates with p53 loss and Kras activation. Gene expression analyses revealed the signature of enhanced oxidative phosphorylation (OXPHOS) in SMARCA4 mutant tumors. We further show that SMARCA4 mutant cells have enhanced oxygen consumption and increased respiratory capacity. Importantly, SMARCA4 mutant lung cancer cell lines and xenograft tumors have marked sensitivity to inhibition of OXPHOS by a novel small molecule, IACS-010759, that is under clinical development. Mechanistically, we show that SMARCA4-deficient cells have a blunted transcriptional response to energy stress creating a therapeutically exploitable synthetic lethal interaction. These findings provide the mechanistic basis for further development of OXPHOS inhibitors as therapeutics against SWI/SNF mutant tumors.
C
ancer genomic studies have demonstrated a high frequency of genetic alterations in multiple subunits of the SWI/SNF chromatin remodeling complex across numerous solid tumors 1 . A meta-analysis of 44 studies revealed that 20% of all tumors have mutations in one or more subunits of this complex 2 . Physiologically, SWI/SNF chromatin remodeling complex uses energy from the hydrolysis of ATP to move, eject or restructure nucleosomes. Thus remodelers dynamically regulate access to chromatin and facilitate gene transcription, DNA replication, DNA repair and recombination 3 . Recent studies have started to shed light on the biochemical consequences of mutations in the SWI/SNF complex including the functional antagonism between SWI/SNF and the Polycomb repressive complexes 4 , the inability of SMARCA4 inactivating mutants to evict the PRC1 complex 5, 6 and impaired enhancer-mediated gene expression regulation by loss of SMARCB1 or ARID1A 7, 8 . Genetic approaches including synthetic lethality screens have indicated the requirement of the residual SWI/SNF complex to drive oncogenic processes when one subunit is inactivated including the discovery that SMARCA2 acts as a synthetic lethal genetic partner to SMARCA4 9 and ARID1B to ARID1A 10 . Importantly, the SWI/SNF complex has been shown to antagonize Myc activity and promote cell differentiation in human cancer 11 . However, despite these highly informative studies and the prevalence of these mutations, our understanding of the mechanistic basis of tumorigenesis by mutations of the SWI/SNF complex at the cellular and tissue level remains rudimentary.
Clinically, there has been substantial success using targeted therapies against mutant EGFR and EML4-ALK fusion in lung cancer patients with the respective genetic alterations 12 . However, most lung cancer patients do not harbor these genetic lesions and do not benefit from these therapies. Thus, lung cancer remains a top cause of cancer mortality. Recent TCGA (The Cancer Genome Atlas) studies have shown that lung adenocarcinoma, a major subtype of lung cancer, harbors frequent mutations in the SWI/SNF complex In lung adenocarcinoma, SMARCA4 and ARID1A are the most frequently inactivated subunits, each at a frequency of 8%. These genetic alterations primarily consist of single nucleotide substitutions (frame-shift, nonsense and few recurrent missense mutations) with infrequent homozygous deletions 1 (compiled in Fig. 1a ). TCGA's comprehensive study validates pioneering works that discovered mutations of SMARCA4 in lung cancer [13] [14] [15] . In the present study, we sought to understand the mechanistic basis of tumorigenesis by mutations in the SWI/SNF complex, and decided to focus on SMARCA4. SMARCA4 is the core catalytic subunit of the SWI/SNF complex and is frequently mutated across multiple cancer types 1, 2, 16 .
Results
Smarca4-deficient genetically engineered mouse model tumors and SWI/SNF deficient human lung adenocarcinomas have increased expression of OXPHOS genes. To investigate the tumorigenesis process in a well-defined genetic context, we initially established a genetically engineered mouse (GEM) model by conditionally inactivating Smarca4 alone or in combination with well-known lung cancer relevant genes, p53 and Kras, selectively in the lung epithelium using adenovirus encoding Cre recombinase following previously established protocols 17 . Interestingly, conditional inactivation of Smarca4 (Smarca4 fl/fl ) alone did not result in lung adenocarcinoma development indicating the requirement of additional genetic alterations to drive tumor development (Fig. 1b) . However, conditional inactivation of Smarca4 together with loss of p53 and activation of oncogenic KRAS (Kras , hereafter called KP) (Fig. 1b) . For subsequent experiments, we routinely used tumors and cell lines derived from these two cohorts. Both KP and KPS tumors are highly pleomorphic, multifocal, show classic histopathologic features of adenocarcinoma, stain positive for pro-surfactant protein C (a marker of alveolar type II cells), and are negative for squamous carcinoma markers p63 and keratin 5, and can be readily detected by micro computed tomography imaging ( Fig. 1c and Supplementary Fig. 1a-d and 2a,b) .
Next, we characterized KP and KPS tumors by performing transcriptomic profiling using RNA -sequencing. Interestingly, gene set enrichment analysis (GSEA) revealed oxidative phosphorylation as the most prominently enriched pathway in KPS tumors compared to KP tumors ( Fig. 1d and Supplementary  Fig. 3a ). Importantly, we performed a similar comparative analysis using RNA-sequencing data from TCGA project of human lung adenocarcinoma tumors which again revealed the oxidative phosphorylation pathway as the most significantly enriched pathway in tumors with mutations in SMARCA4 or ARID1A ( Fig. 1e and Supplementary Fig. 3b) . Prominent examples of genes in the OXPHOS pathway whose expression was increased in SMARCA4-deficient tumors include the master mitochondrial biogenesis co-activator PGC1-α , mitochondrial ATP synthase F0 complex subunit ATP5L, and oxidative stress response genes such as gluthathione S-transferase GSTO7 and GSTO1 (Fig. 1f,g, Supplementary Fig. 3c ). We further utilized gene expression data from an additional human lung cancer patient cohort (BATTLE trial 18 ) to demonstrate the increased expression of prominent OXPHOS genes in tumors with low expression of SMARCA4 ( Supplementary Fig. 3d , Supplementary Table 1) .
As PGC1-α is known to drive mitochondrial biogenesis and respiration 19, 20 , we sought to understand its role in SWI/SNF mutants in more detail. First, we confirmed by immunohistochemistry staining that PGC1-α protein level is increased in KPS tumors (Fig. 1h,  Supplementary Fig. 3e ). Furthermore, similar increases in PGC1-α messenger RNA and protein were observed in KPS tumor-derived cell lines compared to KP cell lines ( Supplementary Fig. 3f ).
SMARCA4-deficient cells have increased mitochondrial respiration.
In order to determine directly the role of PGC1-α in the growth of SMARCA4-deficient cells, we performed a simultaneous shRNA mediated knockdown of PGC1-α in H1299, a SMARCA4-deficient lung cancer cell line ( Supplementary Fig. 3g ). Importantly, we observed profoundly decreased colony formation in parental H1299 cells whereas re-expression of SMARCA4 in an inducible manner rescued the lack of colony formation demonstrating a selective dependence of SMARCA4-deficient cells on PGC1-α (Fig. 2a) .
Consistent with these observations, we identified an increase in the mitochondrial DNA (mtDNA) content of SMARCA4-deficient human lung adenocarcinoma tumors by analyzing the publicly available mtDNA copy number of TCGA tumors 21 ( Fig. 2b) . Additionally, we showed that KPS tumors have higher mtDNA content than KP tumors (Fig. 2c) . It is important to note that with the exception of lung adenocarcinoma, mtDNA content and mitochondrial gene expression are decreased in other tumor types examined compared with their normal counterparts 21 . This is broadly consistent with the generally accepted Warburg phenomenon, whereby cancer cells primarily utilize glycolysis, and not mitochondrial OXPHOS, to generate energy and biomass 22, 23 . We next sought to investigate whether SWI/SNF mutant lung adenocarcinomas behave differently from other tumor types in their mode of energy generation.
First, we asked whether the above observed gene expression changes in OXPHOS actually lead to a functional increase in mitochondrial respiration. To answer this, we utilized KP and KPS murine lung cancer cell lines and SMARCA4-deficient lung cancer cell lines (H1299, H2023 and H2030) that were engineered to express control GFP or SMARCA4 inducibly. Importantly, re-expression of SMARCA4 in these cell lines did not affect the rate of proliferation under regular cell culture media (Fig. 2d, Supplementary Fig. 3h ). We then determined basal mitochondrial respiration and glycolysis using oxygen consumption rate (OCR) and extracellular media acidification rate (ECAR) as surrogates respectively. Interestingly, SMARCA4 re-expression significantly reduced the ratio of OCR to ECAR (Fig. 2e) indicating the presence of an increased rate of basal mitochondrial respiration in cancer cells lacking SMARCA4. Additionally, we observed a consistent increase in basal mitochondrial respiration, spare respiratory capacity and ATP production in the Smarca4-deficient KPS cell lines (Fig. 2f,h ). Furthermore, using the engineered human cancer cell lines we showed a similar increase in basal mitochondrial respiration, spare respiratory capacity and ATP production in SMARCA4-deficient cell lines (Fig. 2i-k and Supplementary Fig. 4a,d) , confirming that the increase in OXPHOS gene expression signature correlates with the increase in functional mitochondrial output both in murine and human cell systems. We also performed metabolomics studies to identify metabolites that are selectively altered in SMARCA4-deficient cells. Interestingly, SMARCA4-deficient cells show an increased amount of two prominent tricarboxylic acid cycle inputs, glutamine and alphaketoglutarate ( Supplementary Fig. 5a,b) . Further, several metabolites that play key roles in the pentose-phosphate pathway (PPP) were elevated in SMARCA4-deficient cells consistent with the known role of the PPP in generating NADPH, a potent antioxidant against oxidative stress and a reducing agent for fatty acid synthesis 24, 25 ( Supplementary Fig. 5c ). Suggesting a state of oxidative stress, SMARCA4-deficient cell lines have elevated levels of reactive oxygen species (ROS) compared with SMARCA4-reconstituted cells ( Supplementary Fig. 6 ).
SWI/SNF mutant lung cancer cells and xenografts are sensitive to inhibition of OXPHOS. Next, we investigated whether SMARCA4-deficient cells are more dependent on OXPHOS for growth than SMARCA4-proficient cells. To answer this we used IACS-010759, a novel small molecule inhibitor of OXPHOS that is currently under clinical development (Fig. 3a) . IACS-010759 is a clinical stage small a b
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Truncating mutation Inframe mutation fl/fl cohort, 95% CI 0.0028 to 0.0638. P values calculated using log-rank (Mantel-Cox test). Both male and female mice are used. c, Immunohistochemistry of KP and KPS tumors indicating positive staining for pro-surfactant protein C (pro-Spc) in both KP and KPS. Although heterogenous, SMARCA4 signal is primarily lost in KPS tumors. The scale bar represents 500 µ M in the primary images and 100 µ M in the insets. Experiments repeated four times on independent tumor tissues. d, Top enriched pathways in KPS tumors compared to KP tumors based on GSEA on RNA-sequencing data generated (n = 4 independent tumors for each cohort). e, Top enriched pathways in ARID1A and SMARCA4 mutated human lung adenocarcinoma tumors revealed by GSEA analysis of TCGA RNA-sequencing data. n = 445 for wild type (WT) and n = 70 for ARID1A and SMARCA4 mutated tumors. f, log 2 normalized expression data showing representative OXPHOS genes, ATP5L, GSTO7 and PGC1-α elevated in KPS tumors. Box-plot representation: from top to bottom: maximum value, 75th percentile, median, 25th percentile and minimum values. n = 4 independent tumors. g, log 2 normalized RNA-sequencing data show that ATP5L and GSTO1 are elevated in SWI/SNF deficient human lung adenocarcinoma tumors. WT n = 445, SWI/SNF deficient n = 70 independent tumors. P values computed using a two-sided Wilcoxon rank-sum test and adjusted for multiple hypothesis testing. Box-plot representation: from top to bottom: maximum value, 75th percentile, median, 25th percentile and minimum values. h, Immunohistochemical staining on tumor tissues using PGC1-α antibody indicates elevated levels in KPS tumors. The scale bar represents 100 µ M in the primary images and 20 µ M in the insets. Experiments repeated three times on independent tumor tissues. 21 . P values computed using a two-sided Wilcoxon rank-sum test. Box-plot representation: from top to bottom: maximum value, 75th percentile, median, 25th percentile and minimum values. c, mtDNA content in KPS and KP tumors (each n = 5 independent tumors). Genomic DNA qRT-PCR based quantification of mitochondrial genome using beta-actin as a control for nuclear genome abundance. Bar graphs show mean and error bars denote s.d. P value computed using a two-tailed Student's t-test; **P = 0.0036. d, Cropped immunoblot showing inducible expression of SMARCA4 in SMARCA4-deficient human lung cancer cell lines by administration of doxycycline (0.5 µ g ml -1 ) with GFP as control. Experiment repeated three times and uncropped images available in Supplementary Fig. 11-1 . Kda = Kilodaltons. e, OCR and ECAR were measured for each of the cell lines using the XF-96 analyzer and ratio computed. Plots show mean values from eight wells (from two experiments) compared by a two-sided Student's t-test; ***P < 0.0001. pMoles/mpH = ratio of picomoles of oxygen molecules consumed to picomoles proton (H)+ change per minute. f,g, A representative trace of OCR values (mean ± s.d.) from a mitochondrial stress test using XF-96 analyzer showing KP-derived cell line (red) and KPS-derived cell line (blue) (f) from which basal respiration and spare respiratory capacity were computed (g). P value computed using a two-sided Student's t-test; ***P < 0.0001. Graphs indicate mean and error bars denote s.d. from eight wells (from two experiments). h, Proton leak and ATP production were computed from f and then P values computed using a two-sided Student's t-test; ***P < 0.0001, **P = 0.0073. Graphs indicate mean and error bars denote s.d. from eight wells (from two experiments). i,j, A representative trace of OCR values (mean ± s.d.) of mitochondrial stress test using XF-96 analyzer showing H1299 parental (blue) and H1299 cell line reconstituted with SMARCA4 (red) (i) from which basal respiration and spare respiratory capacity were computed (j). P values computed from a two-sided Student's t-test; ***P < 0.0001, **P = 0.02. Graphs indicate mean and error bars denote s.d. from eight wells (from two experiments). k, Proton leak and ATP production were computed from i. Graphs indicate mean and error bars denote s.d. from eight wells (from two experiments). P value computed using a two-sided Student's t-test; ***P < 0.0001. ). IACS-010759 (10 or 100 nM) or control DMSO was added to confluent plates, cells were incubated for 24-48 h, fixed and were stained with crystal violet. The experiment was repeated two times. g, In vivo anti-tumor efficacy of IACS-010759 was assessed by treating Ncr-nude mice (n = 15 mice per cohort) subcutaneously implanted with 100,000 cells derived from KPS or KP tumors. IACS-010759 was administered by oral gavage at 7.5 mg kg -1 in methylcellulose carrier once daily for a total of three weeks. Tumor volume was monitored three times per week and plotted as mean ± s.e.m. The vehicle is methylcellulose carrier alone. P values for the KPS group as computed by two-sided Student's t-test are P = 0.46, P = 0.0009, P = 0.0004, P = 0.0008, P = 0.0009 and P = 0.008 for tumor volumes on days 3, 7, 10, 14, 17 and 21, respectively. P values for the KP group as computed by two-sided Student's t-test are P = 0.76, P = 0.37, P = 0.94 and P = 0.52 for tumor volumes on days 3, 7, 10 and 14, respectively. h, In vivo anti-tumor efficacy of IACS-010759 was assessed by treating NSG mice (n = 10 mice per cohort) subcutaneously implanted with PDX model TC388. IACS-010759 was administered by oral gavage at 7.5 mg kg -1 in methylcellulose carrier once daily for seven days for a total of three weeks. Tumor volume was monitored three times per week and plotted as mean ± s.e.m. The vehicle is methylcellulose carrier alone. P values as computed by two-sided Student's t-test are P = 0.89, P = 0.002, P < 0.0001, P < 0.0001, P < 0.0001 and P < 0.0001 for tumor volumes on days 1, 3, 7, 10, 13 and 17, respectively.
molecule that inhibits complex I of the respiratory electron transport chain and has shown a promising safety profile (accompanying article by Marszalek and colleagues 26 ). We performed cell viability assays on 20 human lung cancer cell lines, half of which have inactivating mutations in either SMARCA4 or ARID1A and half of which do not have detectable mutations in the core subunits of the SWI/ SNF complex (Fig. 3b,c and Supplementary Fig. 7a,b) . Notably, we observed that most of the responsive cell lines with GI50 values in the low single digit nanomolar range have mutations in the SWI/ SNF complex whereas most of the wild-type cells are largely resistant to IACS-010759 with the difference being statistically significant (p = 0.0059) ( Fig. 3d and Supplementary Fig. 7b ). Consistent with this, KPS-tumor-derived murine cells were more sensitive to IACS-010759 compared to KP-tumor-derived cell lines (Fig. 3e) . To further confirm dependency of this phenotype on SMARCA4, we performed rescue experiments by doxycycline inducible restoration of SMARCA4 in SMARCA4-deficient lung cancer cell lines, A549, H1299 and H2030. Reconstitution with SMARCA4 resulted in a robust rescue of cell viability when cells were grown to confluency (Fig. 3f) . Next, we assessed whether IACS-010759 has differential antitumor in vivo efficacy by treating mice subcutaneously implanted with xenograft tumors derived from either KP or KPS murine cancer cells. IACS-010759 was able to inhibit growth of established KPS tumors but not KP tumors, demonstrating its selective activity on Smarca4-deficient tumors (Fig. 3g ). Furthermore, we performed an additional in vivo antitumor efficacy study by using a lung cancer patient derived xenograft (PDX) model, TC388, which is deficient in ARID1A. Inhibition of OXPHOS by IACS-10759 has a profound tumor growth inhibitory activity on PDX TC388 (Fig. 3h) . Taken together, our findings demonstrate that cells and tumors with inactivating mutations in a subunit of the SWI/SNF complex (either SMARCA4 or ARID1A) have a profound dependency on OXPHOS compared to wild-type cells revealing a valuable therapeutic window.
SMARCA4 is required for optimal expression of energy deprivation stress response genes. To decipher the inhibitory mechanism of action of IACS-010759 on growth, we focused on redox balance and energy supply as two prominent processes impacted by mitochondrial complex I 27 . Importantly, administration of the anti-oxidant N-acetylcysteine had no impact on the growth inhibitory effect of IACS-010759 ( Supplementary Fig. 8a ). In contrast, removal of glucose from the growth media resulted in a profound increase in sensitivity of cells to IACS-010759, with GI50 values reaching the picomolar range ( Supplementary Fig. 8a ). These data suggest that the most important mechanistic basis of efficacy of IACS-010759 is its capacity to deprive cells of energy and not necessarily massive generation of ROS. Finally, to begin to understand why SWI/SNF mutants in particular are highly dependent on OXPHOS, we focused our investigations on cellular energy supply and demand balance. In principle, SWI/SNF mutants could have either defective glycolysis as an alternate pathway of energy generation or elevated demand through biosynthetic pathways, or a combination of the two.
First, we measured the rate of glycolysis using ECAR and lactate secretion, two well-accepted surrogates. We observed a modest reduction in glycolysis and glycolytic capacity in SMARCA4-deficient cells compared with SMARCA4-reconstituted counterparts (Fig. 4a,b and Supplementary Fig. 8b ). Then we sought to understand the interplay between glycolysis and SMARCA4. Interestingly, we observed that re-expression of SMARCA4 was able to rescue cell death induced by deprivation of glucose from growth media of SMARCA4-deficient A549 and H1299 cells ( Supplementary  Fig. 8c ). This points to a broader role of SMARCA4 in response to energy-deprivation-induced stress. To understand this further, we performed transcriptomic analysis of parental H1299 cells or H1299 cells reconstituted with SMARCA4 under normal growth conditions, IACS-010759 treatment or glucose deprivation (to induce severe energy stress). Remarkably, one of the top most consistently upregulated genes under both IACS-010759 treatment and glucose deprivation only when SMARCA4 is re-expressed was HIF2A, a master regulator of survival pathways activated by various cellular stresses such as hypoxia 28, 29 (Fig. 4c) . Consistent with this observation, GSEA revealed genes in the hypoxia response and glycolysis pathways to be highly enriched when SMARCA4-expressing cells are exposed to energy stress (Fig. 4d) .
In order to show direct regulation of hypoxia and metabolic genes by SMARCA4 we determined the genomic localization of SMARCA4 using chromatin immunoprecipitation-sequencing (ChIP-seq) in H1299 cells after inducible induction of SMARCA4 expression. As expected from its chromatin remodeling activity to facilitate gene expression, SMARCA4 is primarily localized around gene promoters and 5′ regulatory regions ( Supplementary Fig. 9a,b) . GSEA of genomic regions occupied by SMARCA4 reveals that several key pathways including hypoxia response regulation by the hypoxia inducible factor (HIF) network is significantly enriched in SMARCA4 occupancy (Fig. 4e) . We observed that SMARCA4 occupies the promoter region of the HIF2A transcription factor and key glycolytic enzyme HK2 among many other key metabolic regulators (Fig. 4f,g and Supplementary Fig. 9b ). We further validated these observations using ENCODE SMARCA4 ChIP-seq data and analyzing the pattern of genomic regions directly occupied by SMARCA4. GSEA identified the HIF network as the top pathway whose constituent genes are occupied directly by SMARCA4 ( Supplementary  Fig. 9c) . Examples of such genes include HIF2A itself and critical glycolytic enzymes such as hexokinase 2 (HK2) whose promoters were occupied by SMARCA4 ( Supplementary Fig. 9d,e) . Taken together, these data strongly suggest that SMARCA4, by directly occupying the promoters of the energy stress response genes such as HIF2A, facilitates the transcriptional network necessary for effective response and cellular survival. By contrast, in the absence of SMARCA4, cells have a blunted response to energy stress and compromised viability (Figs. 3f and 4c-g and Supplementary Figs. 8 and 9 ). SMARCA4 mutant cells have elevated energy needs for biosynthetic processes. Next, we asked whether SMARCA4-deficient cells have elevated demand for energy because of increased biosynthetic needs. To answer this we focused on two of the most energy intensive anabolic processes in cells, that is, protein synthesis and fatty acid synthesis pathways, which can account for up to 75% of the total cellular energy budget 30 . With the aim of determining the activation status of various signaling pathways that regulate metabolism, we first analyzed TCGA human lung adenocarcinoma protein expression data generated using the reverse phase protein array (RPPA) platform. Amongst the 160 proteins/post-translational modifications assayed, the most significantly downregulated protein in SMARCA4 and ARID1A deficient human tumors was serine 79 phosphorylated acetyl-CoA carboxylase (pACC) (Fig. 5a ). Acetyl-CoA carboxylase (ACC) catalyzes the rate limiting step in long chain fatty acid synthesis and phosphorylation at serine 79 is known to inactivate the enzyme and inhibit cellular fatty acid synthesis 31 . Hence, the reduction in pACC in SWI/SNF deficient tumors is expected to result in increased fatty acid synthesis. Consistent with this observation, we were also able to show markedly reduced pACC by western blot in multiple SMARCA4-deficient cancer cell lines compared with SMARCA4 expressing cells (Fig. 5b) . Next, we hypothesized that inhibition of elevated fatty acid synthesis would reduce energy expenditure and might rescue the growth inhibitory effect of IACS-010759. We treated SMARCA4-deficient H1299 cells using increasing concentrations of IACS-010759 alone or in combination with well-characterized fatty acid synthesis inhibitors, Cpd10v or IPI-9119 32, 33 . We noted a modest but significant rescue of the . P values computed using a two-sided Student's t-test; ***P < 0.0001, **P = 0.0011. c, Left panel: mRNA expression of HIF2A by qPCR in H1299 parental and SMARCA4-reconstituted cell lines grown under regular growth media (RPMI-1640 with 1,500 mg ml -1 glucose, 10% FBS) or no glucose added media (RPMI-1640-glucose, 10% FBS). Results show significantly higher basal as well as induced HIF2A by glucose deprivation upon SMARCA4 expression. The graph shows mean ± s.d. of HIF2A mRNA first normalized to GAPDH and then compared between the SMARCA4-deficient and proficient groups. **P < 0.0001 computed by two-sided Student's t-test, n = 3 independent experiments. Right panel: mRNA expression of HIF2A by qPCR in H1299 parental and SMARCA4-reconstituted cell lines treated with DMSO control or 100 nM IACS-010759 for 24 h. Results show significantly higher basal as well as induced HIF2A by IACS-010759 upon SMARCA4 expression. **P < 0.0001 computed by two-sided Student's t-test. The graph shows mean ± s.d. of HIF2A mRNA normalized to GAPDH. n = 3 independent experiments. d, GSEA analysis of microarray transcriptomic profiling revealed a response to hypoxia and glycolysis as top pathways enriched in response to IACS-010759 treatment in SMARCA4-reconstituted cells. n = 2 independently cell culture grown cells were profiled by microarray for each treatment condition (− Dox, + Dox each with DMSO control or IACS-010759 treatment). e, GREAT 52 was used to perform GSEA on genomic regions occupied by SMARCA4 in H1299 cells stably expressing doxycycline inducible SMARCA4 vector. Cells were treated (+ Dox) or not (− Dox) with doxycycline (0.5 µ g ml -1 ) for five days to induce SMARCA4 expression and with 100 nM IACS-10759 for 24 h to induce energy stress; n = 6,072 genomic regions were used to generate the enrichment plot. f, Representative integrative genome viewer tracks of views of the SMARCA4 ChIP-seq peak on the HIF2A genomic locus. g, Hexokinase 2 genomic locus in H1299 cells re-expressing SMARCA4. The ChIP-seq experiment was performed once for the − Dox and + Dox pair independently. of doxycycline). The experiment was repeated three times and uncropped images are available in Supplementary Fig. 11-2 . c, Viability assay of H1299 parental and SMARCA4-reconstituted cells treated with different doses of IACS-010759 (100, 30 or 10 nM) alone or in combination with the fatty acid synthesis inhibitor Cpd-10V (10 µ M). Results were compared to DMSO control treated cells (set at 100%) and show partial rescue of growth inhibition at each dose by Cpd-10v. The graph represents the mean ± s.d. of n = 4 independent cell culture grown and treated cells. A two-sided Student's t-test was used to derive the P values. **P = 0.0007, **P = 0.0004 and **P = 0.0011 for the 100, 30 and 10 nM groups, respectively. d, Viability assay of H1299 parental and SMARCA4-reconstituted cells treated with different doses of IACS-010759 (100, 30 or 10 nM) alone or in combination with the mTOR inhibitor rapamycin (0.1, 1 or 10 nM). Results were compared to DMSO treated cells (first black bar, set at 100%) and show significant rescue of growth inhibition in a dose-dependent manner by rapamycin. Rapamycin alone did not affect cell growth compared to DMSO. The graph represents mean ± s.d. of n = 3 independent cell culture grown and treated cells. A two-sided Student's t-test was used to derive the P values. For the 10 nM IACS-10759 group, **P < 0.0001, P = 0.007 and P < 0.0001 for 0.1, 1 and 10 nM rapamycin treated cells, respectively. For the 30 nM IACS-10759 group, **P = 0.06, P = 0.0002 and P = 0.0045 for 0.1, 1 and 10 nM rapamycin treated cells, respectively. For the 100 nM IACS-10759 group, **P < 0.0001, P < 0.0001 and P = 0.0005 for 0.1, 1 and 10 nM rapamycin treated cells, respectively. e, A working model: SMARCA4-deficient tumors have an energy imbalance resulting from increased OXPHOS, decreased glycolysis and increased anabolic processes. The cumulative result is energy stress that creates an attractive therapeutic window to target OXPHOS.
growth inhibitory effect of IACS-010759 by co-inhibition of fatty acid synthesis (Fig. 5c and Supplementary Fig. 10 ), supporting the notion that reducing energy expenditure helps cells to survive the energy stress introduced by OXPHOS inhibition. Finally, we investigated whether inhibition of protein synthesis also alleviates energy stress caused by IACS-010759. We treated H1299 cells with IACS-010759 alone or in combination with different doses of rapamycin, a well-characterized mTOR inhibitor that reduces overall protein translation. Although rapamycin alone, up to a concentration of 10 nM, did not have any discernible effect on the growth of H1299 cells, it was potently able to rescue the growth inhibitory effect of IACS-010759 on these cells (Fig. 5d) . Taken together, these data support our proposed model of the critical importance of energy supply and demand imbalance in the selective sensitivity of SWI/ SNF mutants to OXPHOS inhibition (Fig. 5e) .
In summary, our work demonstrates the presence of a complex metabolic rewiring in SWI/SNF mutant lung adenocarcinoma tumors that results in a heightened reliance on OXPHOS. We observed primary defects in energy generation with reduced glycolytic capacity as well as increased energy consumption for biosynthetic pathways in these cells contributing to a state of energy stress (Fig. 5e) . Importantly, this work identified OXPHOS as a therapeutically viable vulnerability of SWI/SNF mutant lung tumors and demonstrated that the small molecule IACS-010759 has a potent and differential antitumor efficacy in such tumors.
Discussion
The similarity between the transcriptomic changes observed in our KPS GEM model and human lung adenocarcinomas with SWI/SNF mutation indicates that the KPS lung cancer model recapitulates, at least in part, relevant human disease processes and could be a valuable experimental model system for future mechanistic and therapeutic investigations. In our GEM model both heterozygous and homozygous loss of SMARCA4 have similar effects on tumor development indicating that SMARCA4 acts as a haplo-insufficient tumor suppressor. This is in contrast to human lung cancer where SMARCA4 loss of heterozygosity is common 13, 34 . This observation could be attributed to differences in the tumor initiating event (that is, targeted manipulation of select genes in the GEM model versus smoking in humans), differences in the cell of origin of tumors as well as the status of cooccurring mutations. As a caveat, our GEM models are on mixed genetic background, which could act as a confounder in some experiments and would benefit from backcrossing to create a pure genetic background.
Previous work has identified lung adenocarcinoma as the only tumor type among the 12 most common carcinomas to have increased mtDNA content compared to adjacent normal tissue 21 . Our work provides additional data that show SWI/SNF mutant lung tumors have elevated mtDNA content compared to wild-type tumors. Although mutations in SWI/SNF are widespread among solid tumors, the existence of similar dependencies on OXPHOS in other tumor types with SWI/SNF mutation is still unclear and needs further investigation. It is also interesting that lung cancer has frequent mutations in LKB1 and KEAP1/NRF2 pathways, which are major integrators of cellular response to energy and oxidative stress. Although glucose and aerobic glycolysis (the Warburg effect) have received the most attention in cancer metabolism studies, several other sources of energy and biomass have been elegantly demonstrated recently including glutamine 35 , autophagy-derived alanine in pancreatic ductal adenocarcinoma (PDAC) 36 , branched-chain amino acids in lung cancer 37 , OXPHOS in oncogene-ablation resistant PDAC cells 38 and serine in LKB1 mutant PDAC 39 . Similarly, our work further expands on the central role of dysregulated metabolism in lung cancer pathogenesis pointing to potential organ/tissue-specific processes that are still not fully understood. Further research including metabolic flux analysis is needed to characterize the dynamic changes in metabolism in SWI/SNF mutants.
It is interesting to note that SWI/SNF chromatin remodeling complex was discovered in screens to identify genes that regulate mating type and sucrose non-fermenting phenotypes in the yeast Saccharomyces cerevisiae whereby snf2 (the yeast homologue of SWI/SNF) mutants lacked the ability to generate energy from sucrose because of their inability to de-repress and express invertase 40 . Interestingly, the same screens identified snf1, whose mammalian homologue is AMPK, a master sensor of cellular energy status that is regulated primarily by LKB1 tumor suppressor 41 . Our study highlights that the fundamental role of the SWI/ SNF complex in facilitating efficient expression of critical genes for energy generation is evolutionarily conserved. It is known that peroxisome proliferator-activated receptor gamma (PPAR-γ ), a master metabolic regulator, requires the SWI/SNF complex for its regulation of adipogenesis, lipid metabolism, thermogenesis and glucose homeostasis 42 . Additionally, Myc activity has been shown to be antagonized by the SWI/SNF complex and is well known to play a major role in metabolic dysregulation of tumors 11, 43 . Even though we did not observe changes in gene expression of major nuclear hormone receptors, metabolic regulators such as PPAR-γ and Myc in our model systems, we cannot rule out their role in the metabolic reprogramming of SWI/SNF mutant tumors because of alteration in the function of these genes at post-transcriptional and post-translational levels. The SWI/SNF complex is also known to regulate several aspects of metabolism under physiological conditions including fatty acid β -oxidation. In particular, the BAF60a subunit induces the expression of genes involved in peroxisomal and mitochondrial fatty acid β -oxidation, including hydroxyacyl-CoA dehydrogenase (Hadha) and acetylCoA acyltransferase 2 (Acaa2). Furthermore, BAF60a has been shown to link the SWI/SNF complexes to the transcriptional coactivator PGC1-α , indicating there is a role for SWI/SNF in hepatic lipid metabolism 44 . Mechanistically, our observations suggest that SMARCA4 facilitates expression of energy stress response genes such as HIF2A that in turn promote a pro-survival transcriptional program. Lack of SMARCA4 resulted in a blunted response to both glucose deprivation and OXPHOS inhibition pointing to a broader role of SMARCA4 in metabolic regulation as well as revealing a potentially attractive vulnerability of these mutants. It has been previously shown that cells that lack TSC2 or LKB1 were exquisitely sensitive to glucose deprivation 45 . This study adds SMARCA4 to this category of genes. Notably, one of the cell lines used in our study, A549, has an inactivating mutation in LKB1 and is known to be exquisitely sensitive to glucose deprivation 46 . Remarkably, re-expression of SMARCA4 in A549 cells, and also in LKB1 proficient H1299 cells, was able to partially rescue the cell death phenotype pointing to a robust contribution of SMARCA4 to survival response independent of the status of LKB1. Our study indicates that the primary therapeutic mechanism of action of IACS-010759 in SWI/SNF mutants is through energy deprivation. This was corroborated by rescue experiments that showed reduction of cellular energy expenditure by inhibiting fatty acid synthesis or protein translation was able to successfully counter the effect of IACS-010759.
The work reported here complements recent studies that have indicated potential strategies to target SWI/SNF mutants. Inhibition of the histone methyltransferase EZH2 has shown a growth inhibitory effect in a subset of SWI/SNF mutants 47 . A recent siRNA screen has indicated that SMARCA4-mutant non-small cell lung cancer cell lines are sensitive to Aurora kinase A inhibition 48 . PARP inhibition has also shown some inhibitory effect in ARID1A mutant ovarian cancer cell lines 49 . In summary, our study identified a fundamental role for SMARCA4 in energy stress response, which creates vulnerability of SMARCA4-mutant tumors to energydepriving therapeutic strategies such as OXPHOS inhibition.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41591-018-0019-5. Immunohistochemistry. Tumors were fixed in formalin for 24 h, paraffin embedded, sectioned and stained according to standard procedures. Briefly, endogenous peroxidases were inactivated by 3% hydrogen peroxide. Non-specific signals were blocked using 3% BSA, 10% goat serum in 0.1% Triton X-100. After antigen retrieval in citrate buffer, slides were stained using respective antibodies Inducible ectopic expression of SMARCA4. eGFP as control or SMARCA4 were cloned into the pInducer20 doxycycline inducible lentiviral vector (Addgene 44012). Lentivirus was produced using standard virus production methods by cotransfecting target and packaging plasmids (psPAX2 -Addgene12260 and pMD2.GAddgene 12259) into HEK293T cells. Cell lines were then transduced with 0.45 μ M filtered and ultracentrifuge-concentrated viral particles with Polybrene (8 μ g ml -1 ). After 16 h of transduction, the media was changed for fresh regular growth media, and 48 h later selection started using G418 (0.2-0.6 μ g ml -1 ). After selection was complete in 72 h, cells were termed stably transduced. GFP or SMARCA4 expression was induced within 24 h of induction with doxycycline 0.5 μ g ml -1 .

GEM
Cell viability assays.
Human and murine cancer cell lines were plated at a density of 2,000 cells per well in a 96-well plate, and cell viability over 72-96 h was assessed in clear bottom 96-well plates (Costar 3603, Corning Incorporated) by CellTiter-Glo (Promega G7572). Compounds were routinely added 24 h after plating by substituting media with drug-containing media. Assay was usually done 72-96 h post treatment with various compounds and determined by the mean of at least four wells per condition, and compared to DMSO-treated wells as control. Luminescence was measured on a POLARstar Omega plate reader and results plotted by GraphPad.
Proliferation and colony-formation assays. Cell growth of SMARCA4 reconstituted and parental cell lines was assayed either through crystal violet staining or by live-cell confluence measurement with IncuCyte (Essen BioScience). Growth curves using IncuCyte were generated by confluence imaging every 2 h with quadruplicate replicates of an initial seeding of 2,000 cells per well in 96-well plates. For colony-formation assays, 500-1,000 cells were seeded in 6-well plates. At the indicated time point (usually 10-14 days), cells were fixed with 80% methanol and stained with crystal violet solution overnight. All experiments were performed in triplicates.
Mitochondrial respiration and glycolysis measurements. OCR and ECAR experiments were performed using the XF-96 Analyzer apparatus from Seahorse Bioscience. Cells were plated (10,000 cells per well) in quadruplicates for each condition the day before the experiment. The next day, the medium was replaced with reconstituted DMEM with 25 mM glucose and 2 mM glutamine (no sodium bicarbonate) adjusted to pH ~7.4 and incubated for 30 min at 37% in a CO 2 -free incubator. For the mitochondrial stress test (Seahorse 101706-100), oligomycin, trifluoromethoxy carbonylcyanide phenylhydrazone (FCCP), and a mixture of antimycin and rotenone were injected to final concentrations of 2 μ M, 0.5 μ M and 4 μ M, respectively. For the glycolysis stress test (Seahorse 102194-100), glucose, oligomycin and 2-deoxyglucose were injected to final concentrations of 10 mM, 2 μ M and 100 mM, respectively. OCR and ECAR were normalized to cell number as determined by CellTiter-Glo analysis at the end of the experiments. OCR and ECAR values were used to compute basal respiration, spare capacity, proton leak, ATP production, glycolysis and glycolytic capacity. Calculations were performed using ExcelMacro Report Generator Version 3.0.3 provided by Seahorse Biosciences and two-sided Student's t-test computed using GraphPad taking the mean and s.d. values provided by Report Generator 3.0.3 and n = 8 (four values from two independent experiments). The formulas were as follows:
basal respiration = (last rate measurement before first injection) -(nonmitochondrial respiration rate), spare respiratory capacity = (maximal respiration) -(basal respiration), proton leak = (minimum rate measurement after oligomycin injection) -(nonmitochondrial respiration), ATP production = (last rate measurement before oligomycin injection) -(minimum rate measurement after oligomycin injection) glycolysis = (maximum rate measurement before oligomycin injection) -(last rate measurement before glucose injection), glycolytic capacity = (maximum rate measurement after oligomycin injection) -(last rate measurement before glucose injection).
Metabolomics via selected reaction monitoring tandem mass spectrometry.
One 15 cm 2 plate of cells (∼ 10-15 million) per sample was extracted with 80% methanol (− 80 °C) for 15 min. Dried metabolite pellets were resuspended in 20 μ l of liquid chromatography/mass spectrometry (LC/MS)-grade water, and 5 μ l aliquots were injected for targeted LC/MS/MS on a 5500 QTRAP hybrid triple-quadrupole mass spectrometer coupled to a Prominence ultrafast liquid chromatography system from 287 selected reaction monitoring transitions with positive/negative polarity switching. Samples were separated on a 4.6 mm internal diameter × 100 mm Amide XBridge hydrophilic interaction liquid chromatography column at 360 μ l min -1 starting from 85% buffer B (100% acetonitrile (ACN)) and moving to 0% B over 16 min. Buffer A was 20 mM NH 4 OH/20 mM CH 3 COONH 4 (pH = 9.0) in 95:5 water/ACN. Q3 (third quadrupole) peak areas were integrated by use of MultiQuant 2.1 software (AB/SCIEX). MetaboAnalyst 2.0 (http://www. metaboanalyst.ca) was used to normalize data, calculate heat maps and perform pathway analysis. All metabolite samples were prepared as biological triplicates.
Transcriptomic profiling by RNA sequencing. RNA was isolated from tumor tissues using Trizol extraction followed by purification with the Qiagen RNAeasy kit as described by the manufacturer. RNA sequencing was performed by the Sequencing and Microarray Facility core at MD Anderson. Libraries were generated using Illumina's TruSeq kit and were sequenced using the Illumina HiSeq2000 Sequencer. RNA sequencing reads of the mouse samples were mapped to mm10 reference genomes respectively using the STAR aligner. For calculation of gene expression, raw count data of each gene were first obtained using HTSeq, normalized by scaling the raw library size using calcNormFactors in the edgeR package in R. Then, we applied Voom transformation to normalized counts and fit a linear model for differential expression analysis using the Limma package. Significantly deregulated genes between any two sample groups were selected (p ≤ 0.05 and fold change ≥ 1.5). Pathway analyses of differentially expressed genes were performed using GSEA and the web-accessible program DAVID (Database for Annotation, Visualization and Integrated Discovery).
Transcriptomic profiling by microarray. Total RNA isolation from H1299 cells was performed with the Qiagen RNeasy kit, according to the manufacturer's instructions. A Human Genome Clarion S chip containing probe sets for > 20,000 characterized genes was used. Sample labeling and processing, hybridization and scanning were performed according to Affymetrix protocols. Briefly, double-stranded complementary DNA was synthesized from total RNA with the GeneChip 3' IVT express kit (Affmetrix), with a T7 RNA polymerase promoter site added to its 3′ end (Genset, La Jolla, CA). Biotinylated cRNAs were generated from cDNAs in vitro and amplified by using the GeneChip 3' IVT express kit. After purification of cRNAs by the RNeasy mini kit (Qiagen, Hilden, Germany), 15 μ g of cRNA was fragmented at 94 °C for 35 min. Approximately 12.5 μ g of fragmented cRNA was used in a 250-μ l hybridization mixture containing herring-sperm DNA (0.1 mg ml -1 ; Promega), plus bacterial and phage cRNA controls (1.5 pM BioB, 5 pM BioC, 25 pM BioD and 100 pM Cre) to serve as internal controls for hybridization efficiency. Aliquots (200 μ l) of the mixture were hybridized to arrays for 16 h at 45 °C in a GeneChip Hybridization Oven 640 (Affymetrix). Each array was washed and stained with streptavidin-phycoerythrin (Life Technologies) and amplified with biotinylated anti-streptavidin antibody (Vector Laboratories) on the GeneChip Fluidics Station 450 (Affymetrix). Arrays were scanned with the GeneArray G7 scanner (Affymetrix) to obtain image and signal intensities. CHP files were then imported into the Affymetrix Expression console and Transcriptome Analysis Console softwares, where normalization and comparison between different groups was performed.
TCGA data analysis. Lung Adenocarcinoma (LUAD) TCGA data was retrieved from Firehose using the getFirehoseData from the RTCGAToolbox R package 54 . We downloaded RNAseq, Mutation, Methylation, Copy Number (GISTIC output) and RPPA data. Mutation data were filtered to consider only frame shift insertions and deletions, in-frame deletions, missense, nonsense, and splice site mutations.
Gene-deficient samples were defined as samples presenting a mutation, deep deletion (GISTIC value = − 2) or scaled expression ≤ − 2. Samples were grouped as deficient or non-deficient to compare different data. P values were calculated using a two-sided Wilcoxon rank-sum test for continuous data, whereas for discrete data a Fisher's exact test was used.
We obtained mtDNA content from TCGA LUAD samples from the supplementary materials of a recent report 21 . The log 2 ratio (tumor mtDNA / normal mtDNA) was used to compare deficient and non-deficient samples. We used blood or normal tissue mtDNA depending on data availability. P values were calculated using a two-sided Wilcoxon rank-sum test or Student's t-test.
BATTLE trial dataset analysis. mRNA gene expression data for SMARCA4 and several OXPHOS genes was collected from an existing human lung cancer cohort, the BATTLE clinical trial 18 . Data processing: Affymetrix GeneChip HuGene-1.0 ST array was used for gene expression profiling. The platform consists of 33,252 probe sets, representing 20,254 unique genes. After receiving all CEL files, quality control (QC) analysis was performed first. In this step, we only kept arrays with the RNA integrity number (RIN) ≥ 4, where RIN is used for assigning integrity values to RNA measurements, and malignant cell percentage ≥ 10. Next, for these arrays past QC, the CEL files were processed using aroma.affymatrix, an R package that is commonly used for HuGene-1.0 ST array data processing. In the package, the Robust Multiarray Analysis algorithm was used for background correction. Then the quantile normalization approach was utilized on the background-corrected expression data. The normalized data was logarithm transformed (base2) for future analysis. We performed Pearson correlation analysis to determine whether there is a significant association between the expression level of SMARCA4 and PGC1-α , ATP5L, COX7A2 and GSTO1.
ENCODE SMARCA4 ChIP-seq data analysis. Bed files from SMARCA4 ChIPseq conducted in HeLa cells was downloaded from the ENCODE project website https://www.encodeproject.org/experiments/ENCSR000EZC/, which contains the detailed experimental setup and conditions similar to other ENCODE projects. Bed files were inputted into the Genomic Regions Enrichment of Annotations Tool (GREAT) and regulator domains identified using GREAT default parameters (http://bejerano.stanford.edu/great/public/html/). False discovery rate (FDR) corrected significant enrichment in MSigDB pathways were retrieved from GREAT output. For selected individual genes, the ENCODE link to the UCSC Genome browser was used to plot SMARCA4 ChIP-seq tracks.
SMARCA4
ChIP-seq and analysis. H1299 cells stably transduced with pINDUCER20-SMARCA4 vector were treated with doxycycline to induce expression of SMARCA4 for five days or left untreated. Cells were then treated with IACS-10759 (100 nM) for 24 h, then harvested and prepared for ChIP-seq. ChIP assays were performed as described 55 with minor modifications. Briefly, ~8 × 10 7 cells were harvested by cross-linking with 1% (wt/vol) formaldehyde for 10 min at 37 °C with shaking. After quenching with 150 mM glycine for 10 min at 37 °C with shaking, cells were washed twice with ice-cold PBS and frozen at − 80 °C for further processing. Cross-linked pellets were thawed and lysed on ice for 30 min in ChIP harvest buffer (12 mM Tris-Cl, 0.1 × PBS, 6 mM EDTA, 0.5% SDS) with protease inhibitors (Sigma). Lysed cells were sonicated with a Bioruptor (Diagnode) to obtain chromatin fragments ~200 to 500 bp and centrifuged at 15,000g for 15 min to obtain a soluble chromatin fraction. In parallel with cellular lysis and sonication, SMARCA4 antibody (Abcam: ab110641) at 5 µ g per 3 × 10 6 cells was coupled to 30 µ l of magnetic protein G beads in binding/blocking buffer (PBS + 0.1% TWEEN + 0.2% BSA) for 2 h at 4 °C with rotation. Soluble chromatin was diluted five times using ChIP dilution buffer (10 mM Tris-Cl, 140 mM NaCl, 0.1% deoxycholic acid, 1% Triton-X, 1 mM EDTA) with protease inhibitors and added to the antibody-coupled beads with rotation at 4 °C overnight. After washing, samples were treated with elution buffer (10 mM Tris-Cl pH 8.0, 5 mM EDTA, 300 mM NaCl, 0.5% SDS), RNAase A and Proteinase K, and cross-links were reversed overnight. ChIP DNA was purified using AMPure XP beads (Agencourt) and quantified using the Qubit 2000 (Invitrogen) and Bioanalyzer 1000 (Agilent).
Library preparation and Illumina sequencing. Libraries for Illumina sequencing were generated following the New England BioLabsNEBNext Ultra DNA Library Prep Kit protocol. A total of 10 cycles were used during PCR amplification for the generation of all ChIP-seq libraries. Amplified ChIP DNA was purified using double-sided AMPure XP to retain fragments ~200 to 500 bp and quantified using the Qubit 2000 and Bioanalyzer 1000 before multiplexing.
ChIP-seq data processing. Raw fastq reads ChIP-seq experiments were processed using FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and quality reads were aligned to the hg19 reference genome using Bowtie version 1.1.2 56 with the following criteria: -m 1 -best. Duplicate reads were removed using SAMBLASTER 57 . To directly compare control and SMARCA4-induced ChIP-seq samples, uniquely mapped reads for each mark were normalized by total reads per condition to ~10 million, sorted and indexed using SAMtools version 1.5 58 .
Identifying ChIP-seq enriched regions. We used model based analysis of the ChIP-seq (MACS) version 1.4.2 59 peak calling algorithm with a P value threshold of 1× 10 -7 to identify SMARCA4 enrichment over 'input' background.
Identification and visualization of unique SMARCA4 binding sites. Unique SMARCA4 binding sites were identified using the concatenate, cluster and subtract tools from the Galaxy/Cistrome web-based platform 60 . Briefly, a shared peak set was first generated by clustering intervals of SMARCA4 -DOX peaks that directly overlapped SMARCA4 + DOX peaks by a minimum of 1 bp. Unique peaks were then identified by subtracting the total number of SMARCA4 peaks in each condition by the shared peak set. To visualize ChIP-seq libraries on the IGV viewer deepTools version 2.4.0 61 was used to generate bigWig files by scaling the bam files to reads per kilobase per million.
Quantitative PCR. Reverse transcription from total RNA was performed from 2 μ g of total RNA using the Superscript III first-strand synthesis system (Invitrogen-Life Technologies) according to the manufacturer's instructions. Quantitative RT-PCR was performed with SYBR Green dye using an Mx3000PTM instrument (Stratagene). PCR reactions were performed in triplicate and the relative amount of cDNA was calculated by the comparative delta computed tomography method using the 18 S ribosomal RNA sequences as a control.
Mitochondrial DNA content measurement. Total genomic DNA including mtDNA was extracted from KPS and KP tumors using a Qiagen tissue genomic DNA isolation kit. Mitochondrial DNA copy number was determined using a qPCR method using a mouse mtDNA quantification kit from Detroit Biosciences (Cat. No. MCN3) following the manufacturer's guidelines.
Immunoblotting. Cells were washed twice in ice-cold PBS, scraped and collected as pellets after centrifugation at 4,000 r.p.m. for 5 min. The pelleted cells were incubated in RIPA buffer with proteinase and phosphatase inhibitors for 15 min. Lysates were then collected and centrifuged at 14,000 r.p.m. for 15 min at 4 °C. Protein concentrations were measured using the DC Protein Assay Kit (Biorad, Cat. No. 5000111). SDS-PAGE and immunoblotting were performed as described previously by manufacturer in pre-cast bis-Tris 4-20% gradient gels (Invitrogen). The following antibodies were used for immunoblotting: PGC1-α (Abcam #54481, 1:1,000), SMARCA4 (Abcam #110641, 1:1,000), GAPDH (Cell Signaling 5174, 1:1,000), phospho-ser79-acetyl-CoA carboxylase (Cell Signaling 3661, 1:1,000), phospho-AMPK Thr172 (Cell Signaling 2535, 1:1,000), AMPK (Cell Signaling 5831, 1:1,000), β -actin (Sigma A5441) and secondary HRP conjugated anti-rabbit (Thermo-Fisher 31460) and anti-mouse (Thermo-Fisher 31430).
In vivo anti-tumor efficacy studies. 1 × 10 5 KP or KPS tumor-derived cells were injected into the flanks of nude female mice at 6 weeks of age (Taconic NcrNu-F). For PDX model TC388, 2 mm tumor fragments were transplanted subcutaneously in NSG mice. Tumor take was monitored visually and by palpation bi-weekly. Tumor diameter and volume were calculated based on caliper measurements of tumor length and height using the formula tumor volume = (length × width 2 )/2. When tumors reached approximately 200 mm 3 , mice were randomized into control and experimental groups. Control mice were treated with vehicle (0.5% methylcellulose) orally every morning on a 5-on 2-off schedule for a total of three weeks. Experimental mice were treated with IACS-010759 (7.5 mg kg -1 ) by oral gavage daily for a total of three weeks. Tumor volume and body weight were measured three times a week.
Micro computed tomography tumor imaging. The mice were anesthetized using ~3% isoflurane for induction and 2% isoflurane for maintenance. The mice were quickly intubated using a 22 gauge × 1 inch intravenous catheter and secured to an animal holder. They were then transferred on the holder to the computed tomography scanner (Precision XRay XRAD 225Cx). The mice were mechanically ventilated during the computed tomography acquisition to allow for a breathe hold. A 20 s three-dimensional computed tomography image was acquired at 60 KVp and 4 mA with a gantry rotation of 3 r.p.m. During the acquisition a breathe hold of the mice was performed for 20 s at 20 cm H2O to fully inflate the lung and minimize motion artifacts. After the imaging procedure the mice were extubated and allowed to recover in a clean warm cage.
Lactate production. Cells were grown in RPMI1640 with 10% dialyzed FBS. Media were collected and lactate secretion was measured using a Trinity Lactate kit. Briefly, 200 μ l of lactate reagent were added to a 96-well plate and mixed with 10-μ l samples (media supernatant) that were diluted 1:10 in PBS. For lactate measurement, the plate was incubated for 1 h at 37 °C and absorbance was read at 540 nm. Raw data were normalized to total protein per well.
Measurement of total cellular ROS.
A dichlorofluorescin diacetate (DCFDA) cellular ROS detection assay (ThermoFisher Scientific) was used to measure total ROS activity within the cells. A total of 2.5 × 10 4 cells per well were seeded on a 96-well plate and allowed to attach overnight. The cells were then stained with 25 μ M DCFDA for 45 min at 37 °C. After staining, the cells were washed and measured using flow cytometry. Kits. The mitochondrial stress test (Seahorse 101706-100) and glycolysis stress test (Seahorse 102194-100) kits and the lactate measurement kit (Trinity Biotech) were purchased from Seahorse Bioscience and used according to the manufacturer's instructions.
Lentiviral
Statistical analyses. Graphpad Prism version 7.0 software was used to conduct the statistical analysis for most of the data unless expressed otherwise. For in vivo anti-tumor efficacy studies, a sample size of at least n = 10 mice per group was used. Differences in GEM model animal survival (Kaplan-Meier survival curves) were analyzed by log-rank (Mantel-Cox) test. Comparisons in large-scale data from public sources (TCGA) were carried out using a two-sided Wilcoxon rank-sum test and adjusting for multiple hypothesis testing. OCR and ECAR measurements were carried out by Seahorse XF96 and data were generated from independent experiments. Derivative values such as respiration rate were computed using a Microsoft Excel Macro (Report Generator) provided by the company. Data are presented as mean ± s.d. except when stated otherwise. Comparisons between two groups were assessed by unpaired two-sided Student's t-test after confirming that the data met appropriate assumptions (normality and independent sampling). Comparisons between more than two groups were performed by one-way ANOVA. Unless otherwise indicated, for all in vitro experiments, three biological replicates were analyzed. Global gene expression profiling from GEM tumors by RNA sequencing were conducted from four independent tumors and GSEA was conducted using the GSEA online tool (http://software.broadinstitute.org/gsea/msigdb/annotate. jsp), which generates enrichment values based on FDR corrected P values.
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